Active prevention of postpartum endometritis in pregnant women with anaerobic dysbiosis and planned cesarian section.

K. V. Voronin, A. M. Alale, I. I. Alale, S. I. Chervonyi


In the structure of inflammatory di­seases postpartum endometritis (PE) retains its leading position. The likelihood of postpartum endometritis deve­lopment after cesarean section increases by 5-10 times compared with spontaneous labor and its frequency has no tendency to decrease. The urgency of PE problem is determined not only by its high prevalence, economic losses, but its possible complications (uterine suture failure and generalization of infection as well). Clinical picture of PE currently is characterized by late manifastation, presence of atypical and asymptomatic forms with mismatched general reaction of the organism and severity of the local pathological process. The leading role in the etiology of PE belongs to conditionaly pathogenic microflora, in the most cases (90%) presence of strict anaerobic nonsporeforming mic­roorganisms, composing part of the normal flora of the genital tract in women. The aim of the study was the development of the principles of active prevention of postpartum endometritis in women with severe vaginal anaerobic dysbiosis while planning cesarean section.


vaginal dysbiosis; diagnosis; pharmacological therapy; prevention of postpartum purulent-septic infection; planned caesarean section

Full Text:



Boldyreva MN. ["Femoflor" study biocenosis uro¬genital tract of women in reproductive age using PCR with the detection result in real time]. Toolkit for doctors. 2010;12. Russian. 2. Kupert MA, Solodun PV, Kupert AF. [Endo¬met¬ritis after childbirth (line group, Features and clinical diagnosis)]. Ross. Journal obstetrics-gynekology. 2003;4:42-46. Russian. 3. Mozheyko LF, Verbitskaya MS. [Sonographic examination of the uterus and uterine blood flow parameters in the diagnosis of postpartum endometritis. Med. panorama]. 2011;6:8-12. Russian. 4. Tirskaya YI, Dolgikh TI, Lazareva LI. [Features of pathogenic organisms in parturients high infectious risk]. Meditsina i obrazovanie v Sibiri. 2013;1:1-16. Russian. 5. Plakhova KI. [Features bacterial vaginosis the¬rapy, associate with Atopobium vaginale, and is charac¬terized by secretions with vagina s Using DNA] Chip: Avtoreferat 14.01.01. «Obstetrics and hynekolohyya». 2007;20. Russian. 6. Cape А, Tuomala RE, Taylor С. [Peripartum bac¬teremia in the era of group B streptococcus prophylaxis]. Obstet Gynecol. 2013; 121(4):812-8. Russian. 7. Polatti F. Bacterial vaginosis, atopobium vaginae and nifuratel. Current Clinical Pharmacology. 2012;7(1):36-40. 8. Hillier SL, Cosentino L, Petrina M. Susceptiblity of bacterial vaginosis (BV)-associated bacteria and lactobacilli to rifaximin, metronidazole and clindamycin. Sex. Transm. Infect. 2013;89:28-29.

GOST Style Citations

1. Болдырева М.Н. "Фемофлор" исследование биоценоза урогенитального тракта у женщин репродуктивного возраста методом ПЦР с детекцией результатов в режиме реального времени: метод. пособие для врачей / М.Н. Болдырева. – М., 2010. – 12 с. 2. Куперт М.А. Эндометрит после родов (группы риска, особенности клиники и диагностики) / М.А. Ку¬перт, П.В. Солодун, А.Ф. Куперт // Рос. вест¬ник акушера-гинеколога. – 2003. – № 4. – С. 42-46. 3. Можейко Л.Ф. Сонографическое исследование матки и показателей маточного кровотока в ди¬а¬гно¬стике послеродового эндометрита / Л.Ф. Можейко, М.С. Вербицкая // Мед. панорама. – 2011. – № 6. – С. 8-12. 4. Особенности патогенной микрофлоры у ро¬диль¬ниц высокого инфекционного риска / Ю.И. Тир¬ская, Т.И. Долгих, Л.И. Лазарева [и др.] // Медицина и образование в Сибири. – 2013. – № 1. – С. 16. 5. Плахова К.И. Особенности терапии бакте¬ри¬аль¬ного вагиноза, ассоциированного с Atopobium vaginae, и характеристика выделений из влагалища с использованием ДНК-чипов: автореф. дис. на соискание учен. степени канд. мед. наук / К.И. Пла¬хова. – М., 2007. – 20 с. 6. Peripartum bacteremia in the era of group B streptococcus prophylaxis / А. Cape, R.E. Tuomala, С. Taylor [et al.] // Obstet. Gynecol. – 2013. – Vol. 121, N 4. – P. 812-818. 7. Polatti F. Bacterial vaginosis, atopobium vaginae and nifuratel / F.Polatti // Current Clinical Pharmacology. – 2012. – Vol. 7, N 1. – P. 36-40. 8. Susceptiblity of bacterial vaginosis (BV)-as¬sociated bacteria and lactobacilli to rifaximin, metro¬nidazole and clindamycin / S.L. Hillier, L. Cosentino, M. Pet¬rina [et al.] // Sex. Transm. Infect. – 2013. – Vol. 89. – P. 28-29.


This work is licensed under a Creative Commons Attribution 4.0 International License